Close Menu

chlamydia

Gen-Probe said this week that Health Canada has granted the company a medical device license for Panther, Gen-Probe's fully automated and integrated molecular testing platform.

Life Tech's 7500 Fast Dx and 3500 Dx Series Genetic Analyzer approved in Japan; Roche files Cobas CT/NG test with FDA.

The platform will combine immiscible phase filtration sample prep with automated amplification and detection, and is expected to have initial applications in point-of-care HIV testing in remote and resource-poor areas of the world. The company also sees the platform being used for decentralized molecular testing in more developed countries.

As part of the deal, FIND will have rights to sell the HIV test, as well as Cepheid's Xpert chlamydia and gonorrhea tests, which will be sold at a discount to the public and the not-for-profit sector in some countries.

Gen-Probe just launched the Panther system in Europe with its initial menu focused on STD tests. The firm believes menu expansion will drive double-digit sales growth for years to come.

The platform will be based on isothermal amplification and its developers aim to cut the amount of time it takes to diagnose STDs to 15 minutes or less at the point of care.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.